Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116082 | 0.83 | KDM4E (0.50) | KDM4EHTTMAOBMAOAMMP2 | |
| SCHEMBL5856000 | 0.83 | KDM4E (0.50) | KDM4EHTTMAOBMAOAMMP2 | |
| SCHEMBL7117419 | 0.83 | KDM4E (0.50) | KDM4EHTTMAOBMAOAMMP2 | |
| SCHEMBL5855233 | 0.82 | KDM4E (0.40) | KDM4EHTTMAOBMAOAFYN | |
| SCHEMBL5857384 | 0.79 | KDM4E (0.46) | KDM4EHTTMAOBMAOALMNA | |
| SCHEMBL7589596 | 0.79 | KDM4E (0.48) | KDM4EHTTMAOBMAOALMNA | |
| SCHEMBL5854508 | 0.76 | CYP19A1 (0.37) | KDM4EMAOBMAOAMAPTALDH1A1 | |
| SCHEMBL7589782 | 0.73 | MAPT (0.55) | KDM4EHTTMAOALMNAMAPT | |
| SCHEMBL5856203 | 0.72 | MAOA (0.39) | KDM4EMAOBMAOAMMP2MMP9 | |
| SCHEMBL5853940 | 0.71 | KDM4E (0.43) | KDM4EHTTMAOBMAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-0944613-B1 | BENZOPYRAN DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-6153768-A | RECEPTOR BLOCKING ANTIESTROGENS HAVING REDUCED SIDE EFFECTS | C & C RESEARCH LABORATORIES (KR) | 2000-11-28 | — | — | US | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0944613-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C Research Laboratories (KR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025916-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | KDM4E 1900/4885HTT 3792/4885MAOB 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.